English
Alzheimer's disease, a progressive neurodegenerative disorder, has long posed significant challenges in terms of accurate diagnosis and effective treatment. Traditional diagnostic tools like MRI, PET scans, and cerebral spinal fluid (CSF) markers are instrumental, yet they come with inherent limitations. Enter blood-based biomarkers, a promising frontier poised to revolutionize the landscape of Alzheimer's disease diagnosis and therapy.
At the recent Clinical Trials for Alzheimer's disease (CTAD 2024) conference in Madrid, Beckman Coulter hosted Drs. Honig, Schindler, and Deckert to learn their thoughts on the advancement of biomarkers in the neurodegenerative space—and the significance, implementation, and future potential of blood-based biomarkers for Alzheimer's disease.
The Importance of Biomarkers in Alzheimer's Disease
Dr. Lawrence Honig kicked off the session by emphasizing the pivotal role of biomarkers in the diagnosis and management of Alzheimer's disease. Biomarkers, a measurable indicator of a biological condition, are crucial for rapidly and accurately diagnosing Alzheimer's disease and for tailoring treatment strategies effectively. Traditionally biomarkers have been measured using imaging techniques and CSF analysis, which although valuable, often fall short due to their invasive nature, cost, and limited scalability.
Current Biomarkers for Alzheimer’s Disease—Limitations and Advantages
Traditional biomarkers, including MRI, PET, and CSF markers, have been the mainstay in Alzheimer's disease diagnosis. However, these methods are not without limitations. MRI and PET scans are costly and not readily accessible, while PET and CSF analysis are both invasive and costly.
Blood-based biomarkers offer a compelling alternative. Dr. Honig elaborated on their advantages, emphasizing the ease of obtaining blood samples and the scalability of such tests. Blood-based biomarkers are non-invasive and cost-effective,1 making them a more patient-friendly option. Due to their ease of use, blood-based biomarkers have the potential to enable earlier and faster diagnoses and to democratize the pathway to diagnosis for Alzheimer's patients.
Biomarker Applications
Dr. Suzanne Schindler presented on the clinical applications of biomarkers, highlighting the importance of accurate diagnosis for effective treatment. Dr. Schindler highlighted that biomarker testing is not recommended for cognitively unimpaired individuals or for those without specific treatment options, emphasizing a targeted approach to testing.
Implementation and Efficacy of Biomarker Testing
Washington University in St. Louis, Missouri, where Dr. Schindler practices, is demonstrating the successful implementation of biomarker testing, having significantly increased their testing volume and developed highly accurate blood tests. Medicare's acceptance of blood tests for Alzheimer's diagnosis further validates their efficacy, allowing for the initiation of anti-amyloid treatments based solely on blood test results. Dr. Amy Deckert, Accurate Diagnosis Program Lead, Healthcare System Preparedness at Davos Alzheimer’s Collaborative (DAC) in Toronto, Canada discussed her efforts to implement blood biomarkers in healthcare systems, focusing on bridging the gap between research and practice. DAC system preparedness uses implementation science to develop generalizable learnings on incorporating innovative biomarkers into clinical practice to improve healthcare system readiness for timely and more accurate diagnosis of Alzheimer’s disease and related dementias.
The Future of Blood-Based Biomarkers
Dr. Schindler envisions a future where blood-based biomarkers redefine the threshold for testing and improve clinical management without invasive procedures. This potential shift could revolutionize how Alzheimer's disease is diagnosed and treated, making early and accurate detection more accessible.
Dr. Honig discussed phase III trial results that indicate the clinical efficacy of blood-based biomarkers, showing promising biomarker changes with the drugs Lecanemab and Donanemab. The potential for using neurological biomarkers to monitor therapy and guide clinical decisions is immense. Blood tests are poised to become a staple in clinical diagnosis, with ongoing trials assessing the effectiveness of anti-amyloid treatments in cognitively unimpaired individuals. However, differences in biomarker changes at the group versus individual level warrant further investigation.
Blood-based biomarkers are transforming Alzheimer's disease diagnosis and management. While traditional cognitive tests and more invasive tests like MRI, PET, and CSF still hold utility, blood-based biomarkers offer a promising avenue for less invasive diagnostics. Blood tests will, of course, need to be validated against PET, MRI, and CSF tests—today’s gold standards—before being brought into primary care.2 The ongoing development of a blueprint to support the implementation of blood-based biomarkers across various health systems is a significant step forward.
The eventual goal is to not just screen symptomatic patients, but to catch patients much earlier—before symptoms develop. As research progresses, these biomarkers may become instrumental in staging patients and guiding therapeutic decisions. With the restricted time clinicians have with their patients and the limited number of neurologists specializing in dementia,3,4 blood-based biomarkers could streamline time to diagnosis, leading to better patient outcomes.
We are committed to identifying novel biomarkers to help combat neurodegenerative diseases such as Alzheimer’s disease.
